Bruker Corporation (BRKR) Stock Price & How to Invest
Last updated July 2026
Short answer
Bruker (BRKR) is a specialized scientific-instruments maker, a technology leader in high-end tools like NMR spectroscopy, mass spectrometry, and microscopy, and investing in it is a bet on research and life-science demand recovering after a soft stretch tied to academic-funding cuts. It trades as a niche, higher-margin peer to giants like Thermo Fisher rather than a broad diversified play.
BRKR stock price
As of 2026-07-27, Bruker Corporation (BRKR) last closed at $60.05, up 36.7% over the past year. Over the past 52 weeks it has traded between $29.35 and $62.70.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Bruker Corporation's investor relations page. Walnut is informational, not investment advice.
What does Bruker Corporation (BRKR) do?
Bruker Corporation designs and sells high-performance scientific instruments used in research, life sciences, materials science, and industrial applications. It operates through four segments: BioSpin (nuclear magnetic resonance spectroscopy and preclinical imaging), CALID (mass spectrometry and chromatography for life-science and applied markets), Nano (surface analysis and microscopy including atomic force microscopy), and BEST (superconducting magnets and X-ray detectors). The company is a recognized leader in specialized, complex applications such as structural biology, proteomics, and advanced materials, competing in what is effectively a duopoly with Thermo Fisher in high-end NMR and mass spectrometry.
The investment picture in mid-2026 is one of a quality niche franchise working through a demand air pocket. Organic revenue has been declining as academic and government research budgets in the U.S., China, and Europe tightened, yet Bruker has beaten reduced expectations, reaffirmed full-year guidance, and leaned on bookings strength in AI-driven semiconductor metrology and scientific software. Management is executing a cost-reduction program to protect margins while it waits for end-market demand and gigahertz-class NMR deliveries to normalize, so the story hinges on whether the current softness is cyclical or more persistent.
What's driving Bruker Corporation (BRKR)?
1. High-end instruments moat
Bruker holds strong positions in NMR, high-end mass spectrometry, and microscopy where technical barriers are steep and it competes mainly against Thermo Fisher. These specialized franchises carry pricing power and recurring service and consumables revenue that cushion instrument-cycle swings.
2. Adjacent growth vectors
Bookings in AI-driven semiconductor metrology and scientific software/digitization each grew over 20 percent recently, pointing to newer end markets beyond traditional academic research. Diagnostics assays (via the RECIPE investment) and applied/industrial demand add avenues that are less exposed to government funding cycles.
3. Margin self-help program
Management is targeting roughly $100 million to $120 million in annualized cost reductions by fiscal 2026 and reaffirmed non-GAAP EPS guidance of about $2.10 to $2.15, implying double-digit earnings growth even with only 1 to 2 percent organic revenue growth. The plan is designed to protect profitability while top-line demand recovers.
4. Acquisition-led expansion
Bruker has been an active acquirer (Chemspeed, Tornado Spectral Systems, Nion, Spectral Instruments Imaging, Nanophoton, and a majority stake in RECIPE), adding capabilities and roughly mid-single-digit revenue contribution. Integrating these into repeatable commercial workflows is a core part of the growth thesis.
What are the risks to Bruker Corporation (BRKR)?
Bruker's largest customers are academic, government, and pharmaceutical research labs, so cuts to U.S. and international research funding directly pressure demand, and organic revenue has been declining as a result. The company flagged an approximately $100 million revenue headwind and $90 million operating-profit impact tied to academic funding disruptions. Heavy acquisition activity introduces integration risk and can mask organic softness, while a large, more diversified competitor in Thermo Fisher can outspend Bruker across the portfolio. Supply-chain exposure to items like high-performance memory chips and liquid helium, plus U.S.-China trade and geopolitical tensions, add further uncertainty. Turning frontier technologies into repeatable, high-volume commercial revenue remains an ongoing execution challenge.
How is Bruker Corporation (BRKR) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Bruker Corporation's investor relations page or your broker.
- Revenue (TTM): ~$3.46B
- Q1 2026 revenue: ~$823M (+2.7% YoY, -4.4% organic)
- FY2026 revenue guidance: ~$3.57B to $3.60B
- FY2026 non-GAAP EPS guidance: ~$2.10 to $2.15
- Market cap: ~$9.8B
- Forward P/E: ~15x to 16x
Bruker beat reduced Q1 2026 expectations (non-GAAP EPS of ~$0.31 versus a ~$0.23 consensus) even as organic revenue fell, and it reaffirmed full-year guidance. The forward earnings multiple of roughly 15x to 16x reflects the market weighing a quality niche franchise against near-term research-spending softness.
Who competes with Bruker Corporation (BRKR)?
Large diversified life-science tools
Thermo Fisher Scientific, Danaher, and Agilent are far larger, broader instrument and consumables companies. Thermo Fisher in particular is Bruker's main rival in high-end mass spectrometry and NMR, and it dwarfs Bruker in scale, revenue, and product breadth.
Specialized analytical instruments
Waters, Revvity, Bio-Rad Laboratories, and Sartorius compete in overlapping niches such as chromatography, spectroscopy, diagnostics, and bioprocessing, where Bruker differentiates through leadership in complex applications like structural biology and proteomics.
Imaging and superconducting technology
In preclinical imaging, X-ray, and superconducting magnets, Bruker faces companies such as GE HealthCare and other specialty detector and magnet suppliers, though these are more fragmented and application-specific markets.
How to invest in Bruker Corporation (BRKR)
There are three common ways to get BRKR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so BRKR sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where BRKR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Bruker Corporation (BRKR)
BRKR is a focused, technology-driven instruments company whose fortunes track research spending, acquisition integration, and its ability to turn frontier science into repeatable revenue.
More on Bruker Corporation (BRKR)
Whether BRKR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BRKR a buy?, and where the stock could go from here in the BRKR stock forecast.
For income investors, whether BRKR pays a dividend and how the payout looks is covered in does BRKR pay a dividend?
Build a basket around BRKR with Walnut
Use Bruker Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Bruker Corporation do?
+
Bruker designs and manufactures high-performance scientific instruments used in research and industry, including nuclear magnetic resonance spectrometers, mass spectrometers, microscopes, and superconducting magnets. Its customers span academic labs, pharmaceutical and biotech firms, and industrial and semiconductor users.
What are Bruker's business segments?
+
Bruker reports four segments: BioSpin (NMR spectroscopy and preclinical imaging), CALID (mass spectrometry and chromatography), Nano (surface analysis and microscopy including atomic force microscopy), and BEST (superconducting magnets and X-ray detectors). The three BSI segments make up the bulk of revenue.
How large is Bruker and what is its revenue?
+
Bruker's trailing-twelve-month revenue is roughly $3.46 billion as of mid-2026, with a market capitalization around $9.8 billion. Full-year 2026 guidance calls for revenue of about $3.57 billion to $3.60 billion.
Who are Bruker's main competitors?
+
Its primary high-end rival is Thermo Fisher Scientific, especially in mass spectrometry and NMR. Other competitors include Agilent, Waters, Danaher, Revvity, Bio-Rad, Sartorius, and, in imaging, GE HealthCare, though most compete in only part of Bruker's portfolio.
Why has Bruker's revenue been under pressure?
+
Organic revenue has declined because academic and government research funding tightened across the U.S., China, and Europe, softening demand for high-end analytical instruments. Bruker estimated an approximately $100 million revenue headwind tied to academic funding disruptions.
How is Bruker responding to weaker demand?
+
Management is running a cost-reduction program targeting roughly $100 million to $120 million in annualized savings by fiscal 2026 to protect margins, while leaning on bookings growth in AI-driven semiconductor metrology and scientific software to offset weakness elsewhere.
How is Bruker valued relative to earnings?
+
Based on full-year 2026 non-GAAP EPS guidance of about $2.10 to $2.15, the stock trades at roughly 15x to 16x forward earnings. That reflects a specialized, higher-margin franchise being weighed against near-term research-spending softness.
What are the main risks to Bruker's investment case?
+
Key risks include prolonged weakness in research funding, integration risk from frequent acquisitions, competition from much larger diversified rivals, supply-chain exposure to items like liquid helium and memory chips, and U.S.-China geopolitical tensions. Walnut is not an investment adviser, so treat these as factors to research, not guidance.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Bruker Corporation's investor relations page or your broker before making investment decisions.